Health Technology · Pharmaceuticals: Major · NSE: SYMBIOTEC · data 2026-10-09

Symbiotec Pharmalab Limited

Health check: Strong (6.6/10 on quality, valuation vs sector, growth and momentum).

Open full analysis — chart, results, balance sheet, red flags →

Key figures

Price

₹1,087.5

Market cap

₹7,032 cr

P/E

—

P/B

—

ROE

—

ROCE

—

Debt / equity

—

Dividend yield

0.00%

1-year return

10.1%

52-week high

₹1,246

52-week low

₹934.2

Operating margin

—

Growth

Revenue (last 12 months)	—
Net profit (last 12 months)	—
Sales growth, 3 years (yearly)	—
Profit growth, 3 years (yearly)	—

Similar companies

Morepen Laboratories Limited (MOREPENLAB) · Bliss GVS Pharma Limited (BLISSGVS) · Supriya Lifescience Limited (SUPRIYA) · Sanofi India Limited (SANOFI) · Innova Captab Limited (INNOVACAP)

The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.

Open SYMBIOTEC in NSE Scanner →